INCHEON, South Korea, March 28, 2022 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), the world’s main agreement advancement and producing corporation (CDMO), hosted its 11th Once-a-year Basic Meeting of Shareholders (AGM) today. 5 matters were being presented and permitted unanimously at this year’s conference, which included the approval of fiscal assertion, appointment of administrators, appointment of director as audit committee member, appointment of audit committee member, and approval of the remuneration restrict for the directors.
“As aspect of our vision, we are now venturing into the 3 main pillars of our multidimensional expansion strategy, encompassing expanded producing ability, ongoing progress in organization portfolio, and larger world footprint,” explained John Rim, CEO of Samsung Biologics in an deal with to the shareholders. “As a foremost CDMO company provider, we will go on to reveal our exceptional business enterprise functions throughout our price chains to eventually contribute to preserving the lives of individuals and construct a superior upcoming for all.”
Same as final 12 months, Samsung Biologics executed an electronic voting system, and the conference was created available for virtual participation through a dwell broadcast. Owing to the ongoing COVID-19 pandemic, the business took precautionary actions all through the conference to make certain the health and fitness and security of all attendees.
Samsung Biologics’ Plant 4 is currently underneath stable building to begin functions by the end of this yr, and the company is steadily securing pre-gross sales with customers. On the comprehensive completion of Plant 4 in 2023, the business is predicted to keep the world’s greatest biomanufacturing ability. The company is even further looking into securing additional sites within just Songdo for its 2nd bio campus, and also overseas in many places to expand its enterprise in nearer proximity to its worldwide consumers.
For additional aspects of the 2022 AGM, please see the reference materials out there underneath the pursuing connection.
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a entirely built-in CDMO providing point out-of-the-art deal enhancement, production, and laboratory testing expert services. With confirmed regulatory approvals, the most significant capacity, and the fastest throughput, Samsung Biologics is an award-successful spouse of preference and is uniquely able to aid the advancement and production of biologics products at each stage of the method while conference the evolving needs of biopharmaceutical providers all over the world. For more details, pay a visit to samsungbiologics.com.
Media Get in touch with
Claire Kim
Senior Director
World Promoting Communication Workforce
Samsung Biologics
[email protected]
Perspective original written content to download multimedia:https://www.prnewswire.com/information-releases/samsung-biologics-retains-11th-annual-normal-assembly-of-shareholders-301512301.html
Resource Samsung Biologics